WE TAKE YOU
A CHANGE IS COMING. ARE YOU READY?
WHO ARE WE
We are a deep technology company with an innovative vision: to go beyond bioprinting.
We are multiplexing advanced electric, magnetic, and electromagnetic field manipulation technologies with 3D bioprinting to develop next generation high-throughput 3D tissues with embedded cyborganic features.
We are pioneers of the new era of regenerative medicine.
We believe that increasing the number of advanced hybrid technologies available for commercial use will set the new quality benchmark of biofabricated products and unlock new, more complex applications in tissue engineering and regenerative medicine. Novel applications include cyborganics, biomechatronics, biosensors, biorobotics, and human-machine interfaces.
By developing and supplying up-to-date, cutting-edge technologies in biofabrication and tissue engineering, we want to offer complete, standardized processes to our customers and make the field of biofabrication more accessible to any working professional with a vision. We empower researchers, developers and producers in various promising fields, thus facilitating their journey from the lab benchtop to the market.
Ourobionics announces its co-founding team and a strategic alliance with Invitech to multiplex advanced tissue engineering technologies with 3D bioprinting and cyborganics
We are officially presenting our co-founding team, formed by professionals with over 50 years of combined expertise in tissue engineering, 3D biofabrication, regenerative medicine, and cyborganics/human-machine interfaces. We have also entered a partnership with Invictech that sets the grounds for developing a multiplex 3D biofabrication platform.
Ourobionics becomes a distribution partner for Humabiologics products in Europe
We are happy to announce Ourobionics entered into a non-exclusive agreement with Humabiologics, a US biotech company specializing in the development and commercialization of human biomaterials for regenerative medicine research applications. The partnership agreement allows Humabiologics to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the European market.